Acadian Asset Management
STOK icon

Acadian Asset Management’s Stoke Therapeutics STOK Stock Holding History

Acadian Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,759
Closed -$284K – 2226
2026
Q1 		$284K Sell
8,759
-5,375
-38% -$176K ﹤0.01% 1494
2025
Q4 		$447K Buy
+14,134
New +$425K ﹤0.01% 1334
2024
Q4 		– Sell
-1,845
Closed -$22K – 2139
2024
Q3 		$22K Buy
+1,845
New +$26.1K ﹤0.01% 1968
2023
Q1 		– Sell
-77,194
Closed -$711K – 1967
2022
Q4 		$711K Buy
+77,194
New +$803K ﹤0.01% 936

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management's STOK Position: Q2 2026 in Review

Acadian Asset Management sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 8,759 shares — an estimated $284K sold.

Acadian Asset Management first reported a position in STOK in Q4 2022 and held it in 4 quarters. The position peaked at $711K in Q4 2022. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Acadian Asset Management reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 8,759 Stoke Therapeutics shares in Q2 2026, an estimated $284K.
  • Acadian Asset Management first reported a position in Stoke Therapeutics in Q4 2022 and held it in 4 quarters.
  • Acadian Asset Management's Stoke Therapeutics position peaked at $711K in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.